Press "Enter" to skip to content

Aurobindo Pharma lines up $200 million capex for FY20

The city-based drug maker spent USD 225 million on capex last year and R&D expenditure was at Rs 872 crore or 4.5 per cent of the revenues for the year, he said.

Original source:

Also Read:   Health activist’s question on generic drugs leaves gynaecologists stumped